The peanut patch and peanut powder for all who are allergic might soon be coming to market! DBV Technologies and Aimmune Therapeutics has developed a patch that slowly exposes the wearer to the peanut allergen to build up tolerance, while Aimmune is working on a peanut powder that patients consume gradually, until they reach a maintenance dose. Both therapies are in Phase 3 clinical trials, and the companies expect to file applications for approval with the FDA by the end of this year.
The other good news is DBV is now working on a “milk” patch.
By Claire Gagné
June 7, 2018
We’re learning more about the two therapies to treat peanut allergies that could soon be available in allergist’s offices in the United States.
DBV Technologies, the makers of the Viaskin peanut patch immunotherapy, and Aimmune Therapeutics, the company behind AR101, a standardized protocol for oral immunotherapy, both presented data at the European Academy of Allergy, Asthma and Immunology (EAACI) conference held in Munich in May.
Both therapies are in Phase 3 clinical trials, and the respective companies expect to file applications for approval with the FDA by the end of this year.
With Viaskin, patients are slowly exposed to their allergen through the skin by wearing a patch, building up tolerance. The therapy has been in clinical trials for years, but the company encountered a setback last fall when it announced its Phase 3 trial failed to meet a main statistical goal set out by the FDA. At the time, the company said it believed its product could still help patients, and that the statistical analysis didn’t tell the whole story. It said it would proceed with its plan to get approval.